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Summary at a glance (less than 50 words) 
We evaluated the association between serum level of CC-16 and asthma, lung function and 
airway responsiveness and showed that decreased serum CC-16 level is associated with 
decreased lung function and higher airway responsiveness in participants without asthma.  
 
Abstract  
Background and objective  
Club cell secretory protein (CC-16) is a sensitive biomarker of airways epithelium integrity 
and because of its presumed relationship to inflammation, has gained increasing interest as 
biological marker in the study of chronic pulmonary diseases. Nevertheless little evidence 
exists of an association between CC-16 serum levels and asthma, lung function and airway 
responsiveness.  
Methods 
Serum CC-16 level was determined by latex immunoassay in 1298 participants from the 
French Epidemiological case-control and family-based study on Genetics and Environment of 
Asthma (EGEA) (mean age 43 years; 49% men, 38% with asthma). Pre-bronchodilator lung 
function (Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) and 
FEV1/FVC) and degree of airway responsiveness, expressed as a function of the dose-
response slope to methacholine test were measured. Standardized residuals (CC-16 z-score) 
obtained by regressing CC-16 level on the glomerular filtration rate were studied in 
association with asthma, lung function and airway responsiveness in participants with and 
without asthma.  
Results 
CC-16 geometric mean level was 12.4 µg/L (range: 2.2 - 70.6 µg/L). In participants without 
asthma, lower CC-16 z-score was associated with impaired FEV1/FVC% (beta=0.50 (95%CI: 
0.06, 0.95) and with higher degree of  airway responsiveness (beta=0.24 (95%CI: 0.09, 0.39)). 
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CC-16 was not associated with impaired lung function or airway responsiveness in participant 
with asthma.  
Conclusions 
Lower CC-16 serum level was associated with impaired lung function and higher degree of 
airway responsiveness, suggesting that serum CC-16 level may reflect early damages of the 
lung epithelium integrity in adults without asthma.  
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Short title 
CC-16 level and airway responsiveness  
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INTRODUCTION 
Club cell protein (CC-16, also called CC10, SCGB1A1 or CCSP) is mainly secreted by the 
club cells along the tracheobronchial tree, diffuses passively into the bloodstream, and is 
finally rapidly eliminated by glomerular filtration 1.  
While the exact function of CC-16 is not known, it is suggested to be a protective mediator in 
the airway inflammatory process 2 and to have protective effects from oxidative stress on the 
respiratory tract 3, 4. Serum CC-16 level is considered as a sensitive biomarker of airways 
epithelium integrity, transiently increasing following acute exposure to pulmonary irritants 
and decreasing after chronic exposures associated with an impairment or reduction of club 
cells. Overall the assay of CC-16 is a sensitive test to allow the detection of early damage to 
the respiratory epithelium 3 and because of its presumed relationship to inflammation, CC-16 
has gained increasing interest as a biological marker in the study of chronic pulmonary 
diseases 5, 6.  
Asthma is a chronic inflammatory disorder of the airways characterised by increased airway 
responsiveness (AR) and associated with accelerate decline in lung function7. Although AR is 
a key characteristic of asthma8 it may occur without asthma-like symptoms or previous 
diagnosis of asthma, which is called asymptomatic AR. 9.  
Findings on the association between CC-16 and asthma are conflicting. No association 
with asthma was observed in adults from a large cross-sectional study10, while a negative 
association was observed in participants with asthma in clinical studies11, 12. Only few large 
epidemiological studies evaluated the association between CC-16 level and lung function, 
providing evidence of a negative association10, 13–15. A negative association between serum 
CC-16 level and AR was described only in one cross-sectional study14, and no study 
evaluated the specific association with asymptomatic AR. Overall there is a lack of large 
epidemiological studies considering together the relations of serum CC-16 with asthma, lung 
function and AR. Our hypothesis is that serum level of CC-16 decreases in participants with 
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asthma, impaired lung function and airway responsiveness. The aim of the present paper is to 
study the associations between serum CC-16 levels and asthma, impaired lung function and 
airway responsiveness in the French epidemiological study on the genetics and environment 
of asthma (EGEA) whom participants with or without asthma have been extensively 
characterized regarding respiratory phenotypes and lung function tests. 
. 
 
METHODS 
Study population 
EGEA is a cohort study based on an initial group of asthma cases, their first-degree relatives, 
and controls (first survey, n=2047)16. At the second survey17, detailed phenotyping was 
performed with lung function tests including methacholine challenge (see Figure 1 and the 
online supplemental population and protocol section). This analysis is based on participants 
who were adults at the second survey (≥ 16 years old, n=1570 adults) with available data on 
asthma, serum CC-16 level and who did not smoke 1 hour before the examination (N=1298).  
 
Biological phenotypes 
Serum CC-16 level was determined with latex immunoassay using a rabbit anti-CC-16 
antibody (Dakopatts, Glostrup, Denmark)18 and purified CC-16 protein as standards (see the 
online supplemental biological phenotypes section).  
Serum creatinine was determined with standard traceable IDMS (isotope dilution mass 
spectrometry traceable) assay and its clearance was calculated by the CKD-EPI (Chronic 
Kidney Disease Epidemiology Collaboration) formula19 which depends on sex and age of 
participants. 
 
Clinical phenotypes 
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Asthma and asthma related phenotypes 
Current asthma referred to the report of asthma attacks or asthma treatment or asthma-like 
symptoms in the past 12 months 20. Participants without current asthma and that never 
reported ever asthma were considered as controls. Based on five asthma symptoms over the 
past 12 months (wheezy breathlessness, woken up by chest tightness and by an attack of 
shortness of breath, attack of shortness of breath at rest and after exercise), the asthma 
symptom score was computed, as previously proposed 21, 22.  
Asthma control was assessed from survey questions and lung function, closely adapted from 
the 2006-2009 Global Initiative for Asthma guidelines 2006, as previously described in 20 (see 
online supplemental population and protocol section for more details).  
 
Pulmonary function 
Pulmonary function test was performed using a standardized protocol with similar equipment 
across centres according to the ATS/ERS guidelines. FEV1 and FVC percent predicted values 
were based on Stanojevic et al. reference equations23.  
 
Airway responsiveness  
Methacholine bronchial challenge test was performed in participants with no medical 
contraindication, unless baseline FEV1<80% predicted or FEV1 post dilution was lower than 
90% of the baseline FEV1, following the same protocol the European Community Respiratory 
Health Survey (ECRHS) 24. Airway hyper-responsiveness (AHR) was defined as a 20% fall in 
FEV1 from the highest FEV1 postdiluent (PD20) during the test with an accumulated dose of 
methacholine. “High AHR” refers to a PD20 related to an accumulated methacholine dose of 1 
mg (PD20 ≤1mg) and “any AHR” refers to a PD20 ≤4 mg. 
The degree of airway responsiveness was quantified by a transformed dose-response slope 
obtained regressing the percentage fall in FEV1 on log10 methacholine dose25 . Low values of 
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slope correspond to high degree of bronchial responsiveness. We referred to participants 
without asthma but with airway responsiveness as “asymptomatic AR”. 
 
Ethics Statement 
Ethical approval was obtained from the relevant institutional review board committees at 
Cochin Port-Royal Hospital and Necker-Enfants Malades Hospital, Paris. Written informed 
consent was signed by kin or guardians of the minors/children and all other adult participants.  
 
Statistical analyses 
Since CC-16 level strongly depends on glomerular filtration rate (eGFR) level (Table 1), we 
obtained eGFR-adjusted residuals by regressing log-transformed CC-16 on eGFR and used 
the standardized residuals (CC-16 z-score, Mean= 0, SD=1) in the subsequent analysis as 
independent variable. Association between CC-16 and asthma was estimated with a logistic 
regression model. Since the expression of CC-16 is known to be inducible by corticosteroids 
26, association with asthma was repeated after excluding participants who used inhaled 
corticosteroids during the previous 12 months (n=265). To account for the specific design of 
the EGEA study analyses on lung function and AR were conducted separately in participant 
with and without asthma and estimates were obtained with linear or logistic regression model, 
where appropriate. All parameters were estimated with generalized estimating equations 
(GEE) with an exchangeable working correlation to account for the potential clustering within 
the families. Estimates were adjusted for sex, smoking status and pack-years, age and height 
when needed. Since CC-16 has shown a time-dependent daily variation,27 blood sampling 
time (range 7 – 20h) was included as covariate. Further, to test whether the association 
between CC-16 and AR was independent from the bronchial calibre of participants, the level 
of FEV1% predicted was added as a covariate in the multivariate model. Finally, since tobacco 
smoke is associated with decreased level of CC-16, as well as with impaired lung function 
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and increased AR, the analyses were stratified by smoking status. All statistical analyses were 
performed using R version 2.14.28 
 
RESULTS 
Characteristics of the sample (Table 1) 
The study population included 1298 participants with a mean age of 43 years (range 16–80 
years). Lung function test was performed by 1278 participants: among them 416 did not 
perform the methacholine test because of poor lung function (n=113) or other reasons (n=303) 
and data on AR were available for 862 participants (see online result section for more details).  
 
CC-16 Serum level  
Overall, serum CC-16 geometric mean (GM) level was 12.4 µg/L, ranging from 2.2 to 
70.6µg/L (Table 1).  CC-16 level was higher in men, increased with age, decreased in 
smokers and with pack-years smoked decreased with blood sampling time and  was 
negatively correlated with eGFR (Table 2). After adjustment for eGFR and blood sampling 
time, the negative associations with age and smoking were confirmed only in participants 
without asthma (beta=-0.04, p=0.06 and beta for trend=-0.08, p=0.006, respectively).    
 
Associations between CC-16 and asthma 
Univariate association between CC-16 level and current asthma (as reported in Table 1) was 
no longer confirmed after adjustment for eGFR (beta = 0.88 (95%CI 0.74, 1.05)) and when 
eGFR adjusted CC-16 z-score was considered as predictive variable (ORadj=0.92 (95%CI: 
0.82, 1.02)). No association was observed between CC-16 z-score and asthma in participants 
not treated by inhaled corticosteroids (n=265, ORadj=0.94 (95%CI 0.82, 1.09)), nor by oral 
corticosteroids or anti-leukotriene (alone or combined, data not shown). 
In participants with asthma, no association was observed between CC-16 z-score and asthma 
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control (p>0.10) or asthma score (p=0.08 for score≥2) and CC-16 levels did not vary with ICS 
use (GM=11.7 (95%CI 8.03, 15.4) µg/L and GM=11.9 (95%CI 8.35, 15.5) µg/L, p =0.16, in 
participants no-ICS and ICS users respectively).  
 
Associations between CC-16 and lung function 
In participants with asthma, no association was observed between CC-16 and lung function 
(table E1, online), and this result was confirmed also in non-ICS users (n=253, p=0.10). 
In participants without asthma (Table 3), reduced FEV1% predicted (borderline significant) 
and FEV1/FVC were associated with reduced CC-16 z-score, considered both on a continuous 
scale and categorized into quartiles (Figure E1, online). Association with lung function was 
higher in current smokers than in never smokers (Figure 2E, online), with statistically 
significant interactions for FEV1% predicted and FEV1/FVC. 
 
Associations between CC-16 and AR 
CC-16 GM level decreased from 12.2 (95%CI: 11.7, 12.7) µg/L in participants who 
performed the methacholine challenge test (N=862) to 11.1 (95%CI 9.75, 12.5) µg/L in 113 
participants who did not performed the test because of poor lung function.  
In participants with asthma no association was observed between CC-16 z-score and AR 
(table E1 online), and this result was confirmed also in non-ICS users.  
In participants without asthma lower CC-16 level was associated with lower level in the dose-
response slope (Figure 2a) borderline higher risk of any AHR (PD20≤4mg) and high AHR 
(PD20≤1mg) (Table 3). These results were confirmed also when FEV1% predicted was 
included in the multivariate model (beta for the slope: 0.20 (95%CI: 0.05, 0.35)) and when 
only participants without any asthma symptom (asthma score<2) were considered (n=465, 
beta for the slope =0.23 (95%CI 0.07, 0.39)). Similar results were observed when CC-16 z-
score was grouped in quartiles (Figure E1, online). Participants in the highest CC-16 z-score 
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quartile were associated with lower slope (betaadj =0.50 (95%CI: 0.08, 0.92)) and a lower risk 
of high AHR (ORadj = 0.30 (95%CI: 0.12, 0.75)) than participants in the lowest CC-16 z-score 
quartile.  
Interaction between smoking and CC-16 z-score was statistically significant for the slope 
(p=0.02) (Figure 2E online). After adjustment for covariates, lower CC-16 z-score was 
associated with lower slope both in current as well as in ex-smokers (betaadj=0.50 (95%CI: 
0.21, 0.79), betaadj=0.24 (95%CI: 0.01, 0.46), respectively).  
 
DISCUSSION  
Using data from a large epidemiological study on asthma, we observed that reduced lung 
function and higher AR were associated with decreased CC-16 level only in participants 
without asthma. No significant association was observed between CC-16 level and current 
asthma. 
The major assets of this study are the sample size, the standardization of the sample collection 
and the availability of clinical parameters. Definition of asthma case is precise 29 leading to a 
very limited risk of false positives. Serum CC-16 level were similar to the reference values in 
healthy non-smokers (between 10 and 15 µg/L on average)3. Prevalence of airway hyper-
responsiveness, measured by a methacholine challenge test was quite high in participants 
without asthma. A possible explanation is that part of the participants without asthma is first 
degree relatives of asthma cases. Nevertheless, this result is consistent with the relatively 
considerable number of asymptomatic participants with AHR reported in cross-sectional 
epidemiologic studies, ranging from 19.3 to 62.4%.30  
CC-16 level was standardized on eGFR so that all the associations were not affected by 
eGFR’s sex and age-related variation. CC-16 decreased with smoking and pack-years 
smoked, varied with blood sampling time and was negatively associated with eGFR, 
consistent with previously published results 31. However, with a cross-sectional approach, 
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causal association between CC-16 and respiratory diseases could not be established. 
We found no association between CC-16 level and asthma. Similarly, no association was 
observed with asthma in 859 participants to population-based multi-centre ECRHS 10 neither 
with asthma and bronchitis in 6531 men aged 67–77 year from a cross-sectional study 32. To 
date, most evidence of an association between CC-16 and asthma comes from small (less than 
100 participants) clinical studies, both in children 33, 34 and in adults 11, 12. A possible 
explanation for this apparent discrepancy is that participants from clinical studies are more 
likely to have severe asthma than participants from population-based studies. Further, clinical 
samples are known to be vulnerable to selection bias that may compromise the 
generalizability of findings.  
We found that FEV1 and FEV1/FVC were associated with serum CC-16 level only in 
participants without asthma. Previously, a positive association between serum CC-16 and 
FEV1 and FVC was observed by in 402 fire-fighters from a cross-sectional study 14 and with 
FEV1% predicted and FEV1/FVC ratio in adults from the general population in the ECHRS 
study 10, after adjustment for the same large range of covariates, including blood sampling 
time. The association between lung function parameters and CC-16 found in our study is 
consistent with previous published results on an association between lung function and 
markers of inflammation, such as C-Reactive Protein 35.  
We observed a negative association between CC-16 level and AR in adults without asthma 
that was confirmed in participants without any asthmatic symptom and was also independent 
from bronchial calibre. To the best of our knowledge this is the first study showing an 
association between CC-16 and asymptomatic AR. Previously, a negative association between 
AR and CC-16, apparently unnoticed by the authors, was observed in 4724 smokers with mild 
to moderate airflow limitation from the Lung Health Study 13 and in 402 fire-fighters, after 
adjustment for smoking and atopic status14. These findings may be related to mild 
inflammatory changes, that are present in airway mucosa of patients with AHR 36 that may 
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lead to damages of airway epithelium and consequent decreased number of club cells in small 
airways 37. Alternatively, genetically determined lower level of CC-16 and subsequent fragile 
epithelium may contribute to the development of asymptomatic AHR. In such case, 
methacholine or any other bronchoconstrictive substance may easily penetrate the lung 
epithelium and induce bronchial hyperreactivity. This hypothesis is supported by the findings 
of Taniguchi and colleagues38, that showed that the A38G polymorphism in the CC-16 gene 
was associated with both plasma CC-16 level and AR in 154 asymptomatic, young, healthy 
adults.  In the EGEA study, we previously found that methacholine AHR was significantly 
related to asthma incidence in asymptomatic participants 9. It could be postulated that 
asymptomatic AR might precede development of respiratory symptoms and asthma36,37 
through mechanisms related with airway inflammation , damage to epithelium integrity and 
structural changes in the airway mucosa39 that are associated with decreased CC-16 levels in 
the airway. Future longitudinal studies, especially on paediatric population, will be useful to 
evaluate the role of CC-16 as a prognostic marker for asthma.  
The lack of association between CC-16 level and lung function or AR in asthmatic group 
could be partly explained by the complex mechanisms, including inflammation and oxidative 
stress that characterizes this disease, leading to less variability of CC-16 level in participants 
with asthma and less sensitivity to variation in AR. Further, the differential association 
between CC-16 and lung function and AR between participants without and with asthma 
support the evidence of heterogeneity of AR in asymptomatic and symptomatic participants 
30.  
In conclusion, we observed that decreased CC-16 serum level were associated with 
asymptomatic airway responsiveness and impaired lung function, only in participants without 
asthma. Those results suggested that serum level of CC-16 may help detecting early damages 
of the lung epithelium integrity. Further longitudinal studies will help in understanding 
whether this information will be used for early detecting asthmatic trait. 
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Table 1: Socio-demographic and clinical characteristics of the participants  
Characteristics All Without 
asthma 
With asthma p 
N 1298 803 495  
Females, % 51.4 53.4 48.1 0.07 
Age, mean (SD), years 43.8 (16.4) 46.4 (15.8) 39.6 (16.5) <0.001 
Smoking status  
and intensity, % 
    
 Lifetime non-smoker 50.1 50.9 48.7 <0.001 
 Ex-smoker, <15 pack-years 19.2 20.2 17.5  
 Ex-smoker, ≥15 pack-years 8.31 8.53 7.94  
 Smoker, <15 pack-years 16.5 12.9 22.4  
 Smoker, ≥15 pack-years 5.9 7.4 3.46  
Asthma symptom score     
 0 13.1 7.33 22.4 <0.001 
 1 86.9 92.7 77.6  
 ≥2 32.9 63.3 9.78  
Lung function test, N 1278 791 487  
FEV1% predicted*, Mean (SD) 97.0 (17.1) 100.8 (15.2) 90.8 (18.2) <0.001 
FVC% predicted*, Mean (SD) 99.7 (14.7) 100.8 (14.5) 98.0 (14.8) 0.001 
FEV1/FVC, Mean (SD) 77.9 (9.32) 79.8 (7.37) 74.9 (11.2) <0.001 
FEV1%predicted*>80%, % 86.9 92.7 77.6 <0.001 
Methacholine  
challenge test, N 
862  540 322  
Dose-response slope, 
N, Mean (SD) 
 
827, 6.34(2.03) 
 
527, 6.95 (1.81) 
 
300, 5.27 (1.96) 
 
<0.001 
Any AHR (PD20≤4mg), N  800 514 286  
28 
Any AHR (PD20≤4mg), N (%)  339 138(26.8),  201 (70.3) <0.001 
 High AHR (PD20≤1mg), N  815  523  292  
High AHR (PD20≤1mg), 
N(%) 
67 67 (12.8) 162 (55.5) <0.001 
Inhaled corticosteroid use, % 20.5 3.5 48.3 <0.001 
Blood sampling time, hour 11.6 (2.17) 11.6 (2.17) 11.7 (2.17) 0.3 
Serum Creatinine, mg/dL, 
Mean (SD) 
 
0.81 (0.16) 
 
0.80 (0.17) 
 
0.82 (0.16) 
 
0.05 
eGFR, mL/min*1.73m2, 
Mean (SD) 
 
100.2 (18.8) 
 
98.6 (18.8) 
 
102.7 (18.5) 
 
<0.001 
CC-16, µg/L, GM (SD) 12.4 (1.87) 12.8 (1.88) 11.8 (1.85) 0.03 
 
AR: Airway responsiveness; AHR: Airway Hyper-responsiveness; CC-16: Club cell secretory 
protein; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GFR: 
Glomerular Filtration Rate; GM: Geometric Mean; PD20: 20% reduction in FEV1 after 
methacholine challenge test (1 mg or 4 mg cumulative dose); SD: Standard Deviation; 
*Stanojevic reference equations. 
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Table 2. Association between participants’ characteristics and CC-16 level 
 Non asthmatics (N=803) Asthmatics (N=495) 
 N CC-16 GM / 
 Beta (95%CI) † 
 Beta‡ N CC-16 GM /  
Beta (95%CI)† 
 Beta‡ 
Sex       
Males 374 13.1 (12.3,13.9)  257 12.4 (11.5,13.3)*  
Females 429 12.5 (11.8,13.3) -0.03 238 11.2 (10.4,12.1) -0.10** 
Age, 10 years  0.05 (0.02, 0.08)*** -0.05**  0.07 (0.04, 0.10)*** 0.02 
Smoking status       
Lifetime non-smoker 406 13.1 (12.3,13.9) ** -0.04** 239 11.6 (10.7,12.5)* -0.01 
Ex smoker, <15 pack-years  179 13.8 (12.6,15.0)  102 13.3 (11.8,15.0)  
Ex-smoker, >15 pack-years 50 12.0 (9.78,14.7)  23 13.0 (10.2,16.6)  
Smoker, <15 pack-years 123 12.1 (10.8,13.6)  115 11.1 (9.93,12.5)  
Smoker, >15 pack-years 39 9.34 (7.61,11.5)  12 8.99 (5.77,14.0)  
Blood sampling time, hour 801 -0.03 (-0.05, -0.008)** -0.04*** 492 -0.04 (-0.07, -0.02)*** -0.05*** 
Serum creatinine, mg/dL 803 0.79 (0.55, 1.03)***  495 0.48 (0.16, 0.79)**  
eGFR estimated,  
mL/min*1.73m2 
803 -0.008 (-0.01, -0.006)*** -0.01*** 495 -0.006 (-0.009, -0.003)*** -0.01** 
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CC-16: Club cell secretory protein; CI: Confidence Interval; eGFR: Glomerural Filtration Rate; GM: Geometric Mean;  
† Overall P-values for the association between each participant characteristic and CC-16 level 
‡ Beta coefficients and p-values from one multivariate regression model with sex, age, smoking status (test for trend), sampling time and 
glomerular filtration rates as covariates and CC-16 z-score as outcome variable 
 *p<.10, ** p<.05, *** p<.001.  
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Table 3. Association between airway responsiveness and lung function and GFR-standardized CC-16 z-score in participants without asthma 
  N Unadjusted beta/ 
OR (95%CI)  
p Adjusted beta 
/OR (95%CI)  
p 
Lung function measurements      
FEV1 % pred. Values*,† 791  1.15 (0.05,2.24)  0.04  1.01 (-0.07,2.08) 0.07 
FVC % pred. Values*,† 791  0.57 (-0.45,1.60)  0.27  0.42 (-0.61,1.45)  0.43 
FEV1/FVC† 762 0.62 (0.12,1.12)  0.02  0.50 (0.06,0.95)   0.02 
Methacholine challenge test, N,      
Dose-response slope, Mean (SD) 527 0.25 (0.09,0.41) 0.001  0.21 (0.06,0.37)  0.005 
No AHR (reference) 376 1 1 - 
Any AR (PD20≤4mg) ‡, % 138  0.83 (0.68,1.00) 0.048 0.82 (0.66,1.02) 0.07 
High AR (PD20≤1mg) ‡, % 67 0.70 (0.54,0.90)  0.006  0.65 (0.48,0.87)  0.004 
AR: Airway responsiveness; AHR: Airway Hyper-responsiveness; CC-16: Club cell secretory protein; CI: Confidence Interval; FEV1: forced 
expiratory volume in 1 second; FVC: Forced Vital Capacity; GFR: Glomerular Filtration Rate; OR: Odds Ratios; PD20: 20% reduction in 
FEV1 after methacholine challenge test (1 mg or 4 mg cumulative dose); SD: Standard Deviation; 
* FEV1% predicted and FVC% predicted ranged from 0 to 1 and were obtained using Stanojevic reference equations 40.  
† Beta estimates (95%CI) for a unitary increase in the GRF adjusted CC-16 z-score, estimated with GEE linear regression models 
32 
‡ Odds ratios (95%CI) for a unitary increase in the GRF adjusted CC-16 z-score, estimated with GEE logistic regressions models 
All estimates are reported as unadjusted and adjusted for age, smoking status and pack-years (never smokers, ex-smokers that smoked ≤15 
pack-years, ex-smokers that smoked ≥15 pack-years, current smokers with <15 pack-years and current smokers with ≥15 pack-years), blood 
sampling time, sex (for FEV1/FVC, any and high AHR and AR) and height (for FEV1/FVC) 
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Figure 1. Flow chart of the EGEA population and the participants included in the study 
 
Figure 2. CC-16 according to the dose-response slope by asthmatic status 
Legend: CC-16 GM level by dose-response slope (grouped in quartiles. The p-values refer to test for trend among participants who did 
perform the methacholine challenge test. The first bar in each group is related to participants who did not perform the test because of baseline 
FEV1 <80% predicted or FEV1 post dilution <90% of the baseline FEV1.  
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Serum CC-16 level is associated with asymptomatic Airway responsiveness in adults from the 
EGEA study  
 
SUPPLEMENTAL DATA 
 
METHODS 
Population and protocol  
The EGEA combines a case-control and family study of adult and childhood asthma 
(http://egeaintranet.vjf.inserm.fr/). The first EGEA survey (EGEA1) was conducted from 1991 to 
1995, and the protocol and descriptive characteristics have been described elsewhere 1. Briefly, 388 
asthmatic cases, recruited in 5 chest clinics, 1244 first-degree relatives of cases, and 415 
population-based controls were recruited (total, n= 2047). A 12-year follow-up of this population 
was conducted from 2003 to 2007 (EGEA2) in 5 centres in France (Grenoble, Paris, Lyon, 
Marseille, Montpellier). Participants were contacted by postal questionnaire, and non-responders 
were further contacted by telephone (step 1). Among the alive cohort (n = 2002), 92% (n = 1845) 
completed the short self-questionnaire. Responders were invited to participate in the second phase 
of the study (step 2). The complete examination was mostly performed in clinical centers (n = 1316; 
85.3%). However, to improve the follow-up rate, some participants were examined at home (n = 72; 
4.7%) or answered questionnaires by phone (n=78; 5.0%) or mail (n=77; 5.0%). Finally, 77% of the 
alive cohort (n= 1543) completed at least a detailed questionnaire. In addition, 58 new family 
members where included in the study at the second survey. Written consent was obtained from all 
participants at both surveys. Ethical approval to carry out the study was obtained for both surveys 
from the relevant committees (Cochin Royal Hospital, Paris, for EGEA1, and Necker-Enfants 
Malades Hospital, Paris, for EGEA2). Examination procedures included a detailed questionnaire, 
with questions on asthma and respiratory symptoms, treatment, allergic rhinitis, active smoking, 
and exposure to environmental tobacco smoke. Participants had blood samples that allowed to 
measure total IgE in a centralized laboratory (n= 1421; 88.8%). Spirometry was performed by using 
a standardized protocol with similar equipment across centers according to the American Thoracic 
Society / European Respiratory Society guidelines 2 to measure FEV1 (n= 1414; 88.3%). Skin prick 
tests to 12 aeroallergens (cat, Dermatophagoides pteronyssinus, Blattela germanica, olive, birch, 
Parieteria judaica, timothy grass, ragweed pollen, Aspergillus, Cladospo- rium herbarum, 
Alternaria tenuis, Cypress) were performed in 1326 participants (82.8%). Sensitization was defined 
by the presence of at least 1 positive skin test (mean wheal diameter ≥3 mm). Strong efforts were 
made to standardize all the examination procedures across centers and to minimize missing data. A 
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quality management approach was followed for the implementation of the EGEA2 data collection, 
and an International Organization for Standardization (ISO) 9001:2000 certification was obtained 
(http://www.afaq.org/certification5262711141114). 
 
Phenotype definitions 
Inhaled corticosteroid use was defined by a positive answer to the question, ‘‘Have you used 
inhaled corticosteroids to help your breathing at any time in the past year?’’ with an exhaustive list 
of medications available in France at the time of the study.  
Participants were defined with (1) controlled asthma if all the following features were present: no 
more than 1 instance per week of trouble breathing (defined by the answer to ‘‘How often have you 
had trouble with your breathing because of your asthma in the past 3 months?’’) and no asthma 
attack in the last 3 months (defined by the answer to ‘‘How many asthma attacks have you had in 
the past 3 months?’’), no nocturnal symptoms (woken up because of asthma or by an attack of 
shortness of breath) in the last 3 months, use of short-acting β2-agonist inhalers ≤2/wk in the last 3 
months, no use of oral corticosteroids in the past year, FEV1 ≥80%predicted; (2) partly controlled 
asthma if 1 or 2 of these features were absent; and (3) uncontrolled asthma if ≥3 of these features 
were absent or if respiratory problems had caused hospital or emergency admissions in the past year 
or use of oral corticosteroids in the past year or ≥12 asthma attacks in the past 3 months. 
 
Biological phenotypes 
Serum CC-16 level was determined with latex immunoassay using a rabbit anti-CC-16 antibody 
(Dakopatts, Glostrup, Denmark) and purified CC-16 protein as standards (home made at the 
Laboratory of Toxicology Applied Pharmacology, Faculty of Medicine, Catholic University of 
Louvain, Belgium). When pooled normal sera is fractionated by fast protein liquid chromatography 
on Sephacryl S-200 (Pharmacia Biotechnology, Uppsala, Sweden), CC-16 elutes as a single 
component with an apparent Mr of ~16 kD, and is indistinguishable from the native protein. To 
avoid possible interference by complement, rheumatoid factor, or chylomicrons, the plasma 
samples were pretreated by heating at 56º C for 30 min and by the addition of polyethylene glycol 
(16%, 1:1 [vol/vol] and trichloroacetic acid (10%, 1:40 [vol/vol]). After overnight precipitation at 
4ºC, the samples were centrifuged (2,000x g for 10 min) and CC-16 was determined in the 
supernatants. All samples were analyzed in duplicate at two different dilutions. The assay has a 
detection limit of 0.5 ng/ml and an average analytical recovery of 95%, with the intra- and inter-
assay coefficients of variation ranging from 5 to 10% 3. Serum creatinine was determined with 
standard traceable IDMS (isotope dilution mass spectrometry traceable) assay.  
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Glomerular filtration rate (eGFR) was estimated using the CKD-EPI (Chronic Kidney Disease 
Epidemiology Collaboration) formula 4 (see below) and expressed as mL/min*1.73m2:  
 
eGFR = 141 X min(Scr/κ,1)α X max(Scr/κ,1)-1.209 X 0.993Age X 1.018 [if female] X 1.159 [if black], 
where Scr is the serum creatinine level (mg/dL), κ= 0.7, if female or 0.9 if males, α=–0.329, if 
females, or –0.411, if males  
 
RESULTS  
Characteristics of the sample 
Participants with asthma were younger and smoked less frequently than participants without 
asthma. Lung function parameters were lower and AHR (PD20≤4mg) was more frequent in 
participants with asthma than in those without asthma.  
Among participants who performed the methacholine test (N=862), 800 (514 with asthma and 286 
without) had information about their reduction in FEV1 after a provocative dose of methacholine of 
4mg (PD20<4mg).  339 out of 800 (42.4%) had PD20<4mg and among those 138 (138/514=26.8) 
were without asthma and 201 (201/286=70.3) were with asthma. For what concern PD20<1mg, data 
were available for 815 participants (523 without asthma and 292 with asthma). Among those, 67 
(12.8) with asthma and 162 (55.4) controls reported PD20<1mg.  
Participants who performed the methacholine test were more often females (54% vs. 45%, 
p=0.007), were younger (mean age=41 vs. 50 years, p<0.001), smoked more frequently (24.3 % vs. 
19.6%, p=0.06), had higher level of eGFR (mean value: 103 vs. 95 mL/min*1.73m2, p<0.001, age 
and sex adjusted p<0.001) and higher FEV1 (mean value: 3.5 vs. 2.9 L, p<0.001, age and sex 
adjusted p<0.001) than participants who did not (N=416).   
 
Table E1. Association between asthma, airway responsiveness and lung function and GFR-
standardized CC-16 z-score in participants with asthma 
  N Unadjusted beta/ 
OR (95%CI)  
p Adjusted beta 
/OR (95%CI)  
p 
Lung function measurements      
FEV1 % predicted*,a 791 1.53 (-0.21,3.27)  0.09 1.53 (-0.21,3.27)  0.19 
FVC % predicted*,a 791 0.44 (-0.82,1.71)  0.49 0.44 (-0.82,1.71)  0.67 
FEV1/FVCa 762 0.86 (-0.28,2.00) 0.14 0.86 (-0.28,2.00) 0.15 
Methacholine challenge test, N      
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Dose-response slopea 300 0.05 (-0.16,0.26)   0.63  0.08 (-0.13,0.30)  0.45 
No AHR (ref) 85    
Any AHR (PD20≤4mg)b, % 201 1.04 (0.78,1.39)    0.77  0.99 (0.72,1.36)  0.97 
High AHR (PD20≤1mg) b, % 162 1.06 (0.82,1.36)   0.65 1.07 (0.81,1.41)  0.62 
AR: Airway responsiveness; AHR: Airway Hyper-responsiveness; CC-16: Club cell secretory 
protein; CI: Confidence Interval; FEV1: forced expiratory volume in 1 second; FVC: Forced Vital 
Capacity; GFR: Glomerural Filtration Rate; GM: Geometric Mean; OR: Odds Ratios; PD20: 20% 
reduction in FEV1 after methacholine challenge test (1 mg or 4 mg cumulative dose); SD: Standard 
Deviation; 
* FEV1% predicted and FVC% predicted ranged from 0 to 1 and were obtained using Quanjer 
reference equations  
a Beta estimates (95%CI) for a unitary increase in the GRF adjusted CC-16 z-score, estimated with 
GEE linear regression models 
b Odds ratios (95%CI) for a unitary increase in the GRF adjusted CC-16 z-score, estimated with 
GEE logistic regressions models 
All estimates are reported as unadjusted and adjusted for age, smoking status and pack-years (never 
smokers, ex-smokers that smoked ≤15 pack-years, ex-smokers that smoked ≥15 pack-years, current 
smokers with <15 pack-years and current smokers with ≥15 pack-years), blood sampling time, sex 
(for FEV1/FVC, any and high AHR and AR) and height (for FEV1/FVC) 
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Figure E1. Association between lung function, AR and GFR-standardized CC-16 z-score grouped in quartiles in participants without asthma 
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Legend: prevalence of AHR and degree of AR by quartiles of CC-16 z-score. Asterisks represent P-values obtained by comparing the odds ratio of 
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having AHR (Any AHR (PD20≤4mg) or High AHR (PD20≤1mg)) or the average degree of AR, for each quartile of CC-16 z-score, using the first 
quartile as reference, after adjustment for blood sampling time, sex, age and smoking status. ((*) P<0.10, (**) P<0.05, (***) P<.001). 
 
 
OLD VERSION TO BE DELETED 
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Figure E2. Association between the dose-response slope and lung function and  GFR-
standardized CC-16 z-score stratified by smoking status in non- asthmatic participants.  
 
Legend: regression coefficients (Beta) and 95%CI for the association between CC-16 z-
score and Airway responsiveness, estimated through GEE logistic and linear models, 
stratified by smoking status and adjusted by age, sex and sampling time and height (for 
FEV1/FVC). The P-values refer to the interaction between smoking status and the CC-16 z-
scores. 
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